Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 11/20 | 0.64 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28389498 | 0.78 | NOTUM (0.70) | NOTUMBRD4HSD17B3HTR1ADRD2 | |
| SCHEMBL14294095 | 0.78 | NOTUM (1.00) | NOTUMBRD4HSD17B3DRD2HTT | |
| SCHEMBL8482798 | 0.74 | NOTUM (0.69) | NOTUMBRD4HSD17B3HTR2A | |
| SCHEMBL28360710 | 0.74 | NOTUM (0.64) | NOTUMBRD4HSD17B3HTR1ADRD2 | |
| SCHEMBL14543698 | 0.74 | NOTUM (0.64) | NOTUMBRD4HSD17B3HTR1ADRD2 | |
| SCHEMBL4130538 | 0.74 | NOTUM (0.64) | NOTUMBRD4HSD17B3HTR1ADRD2 | |
| SCHEMBL10246760 | 0.74 | NOTUM (0.64) | NOTUMBRD4HSD17B3HTR1ADRD2 | |
| SCHEMBL16376799 | 0.74 | ACHE (0.38) | NOTUMBRD4HTR1ADRD2HTR2A | |
| SCHEMBL23198365 | 0.73 | NOTUM (0.62) | NOTUMBRD4HSD17B3HTR1ADRD2 | |
| SCHEMBL27603646 | 0.73 | NOTUM (0.62) | NOTUMBRD4HSD17B3HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | NOTUM 3045/4885BRD4 94/4885HSD17B3 2542/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | NOTUM 4244/4885BRD4 248/4885HSD17B3 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.